Ovarian cancer: progress and continuing controversies in management
- 30 September 2002
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 38 (13), 1701-1707
- https://doi.org/10.1016/s0959-8049(02)00161-2
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2002
- Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2002
- Caelyx®: phase II studies in ovarian cancerEuropean Journal Of Cancer, 2001
- Treatment of advanced ovarian cancerEuropean Journal Of Cancer, 2001
- The integration of anthracyclines in the treatment of advanced ovarian cancerInternational Journal of Gynecologic Cancer, 2001
- Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian CarcinomaGynecologic Oncology, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II study of gemcitabine in previously platinum-treated ovarian cancer patientsAnti-Cancer Drugs, 1995